The Food and Drug Administration (FDA) has updated the safety label for the irritable bowel syndrome (IBS) medication Viberzi (eluxadoline) to include new warnings regarding pancreatitis and sphincter of Oddi spasm, a loss of normal function of the smooth muscle that surrounds the end portion of the common bile duct and pancreatic duct, which can cause obstruction of bile flow and obstruction to the flow of pancreatic juice into the intestine. The label now discourages use of the IBS drug in patients without a gallbladder because they are at increased risk of developing serious adverse reactions of pancreatitis and/or sphincter ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.